Printer Friendly
The Free Library
5,661,123 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Kyowa Hakko Produces Tablet Version of Cholesterol-lowering CSPHP; Tablets Enable CSPHP to be Incorporated into Dietary Supplements.


Business Editors/Health/Medical Writers

Supply Side West

TOKYO--(BUSINESS WIRE)--Sept. 24, 2003

Kyowa Hakko Kogyo Co., Ltd., one of Japan's leading developers of pharmaceutical and biotechnology products, has produced a tablet version of CSPHP(R)*, its novel cholesterol-lowering food ingredient. This development will allow dietary supplement makers to make CSPHP-based cholesterol-lowering tablets or capsules for consumers to incorporate into their daily diet, and follows the successful launch of a liquid version of CSPHP in July 2003.

Kyowa Hakko will be showcasing the active ingredient, CSPHP, along with tablets and the data from its latest trials at the Supply Side West show in Las Vegas from October 1-3, 2003. Kyowa will also demonstrate its in-house capsuling and bottling capabilities in the USA, which enable supplement companies to quickly launch new products to the market, and will outline the consulting service it offers to help manufacturers devise effective advertising that meets regulatory requirements.

A randomized ran·dom·ize  
tr.v. ran·dom·ized, ran·dom·iz·ing, ran·dom·iz·es
To make random in arrangement, especially in order to control the variables in an experiment.
, double blind placebo controlled trial controlled trial Clinical research A clinical study in which one group of participants receives an experimental drug while the other receives either a placebo or an approved–'gold standard' therapy. See Blinding, Double-blinded.  of 75 subjects, reported in the Japanese Pharmacology & Therapeutics journal (vol.31, no. 7), concluded that 3 grams per day of CSPHP in tablet form over 4 weeks or beyond had a significant effect in reducing serum cholesterol levels in mildly hypercholesterolemic subjects (serum total cholesterol: 220 - 240mg/dl). At the same time, 1.5g seemed to possess potential to lower cholesterol in a dose responsive manner.

"CSPHP is an increasingly popular and important cholesterol lowering agent in the growing Japanese functional food market, and we are excited to be adding the tablet version to the powder and liquid formats already being widely adopted in the industry," said Tadayasu Furukawa, President of Kyowa Hakko's Food Company. "We expect that its proven efficacy in lowering cholesterol will appeal to millions of health-conscious consumers looking for Looking for

In the context of general equities, this describing a buy interest in which a dealer is asked to offer stock, often involving a capital commitment. Antithesis of in touch with.
 effective dietary supplements."

According to the National Heart, Lung, and Blood Institute's National Cholesterol Education Program The National Cholesterol Education Program is a program managed by the National Heart, Lung and Blood Institute, a division of the National Institutes of Health. Its goal is to reduce increased cardiovascular disease rates due to hypercholesterolemia (elevated cholesterol , about 50 percent of American adults have elevated blood cholesterol levels -- one of the key risk factors for heart disease, the number one killer of both men and women in the U.S.

Cognizin(R), a branded citicholine ingredient for brain health, and amino acids will also be showcased.

*About CSPHP:

CSPHP is a novel cholesterol-lowering compound that combines soy protein hydrolyzate and soy phospholipids to block the absorption of cholesterol in the intestine. CSPHP also has a unique property that increases the production of healthy HDL cholesterol HDL cholesterol
n.
See high-density lipoprotein.


HDL Cholesterol
About one-third or one-fourth of all cholesterol is high-density lipoprotein cholesterol.
 in hypercholesterolemic volunteers.

Controlled trials, conducted among hypercholesterolemic volunteers, have indicated that 3 grams of CSPHP taken every day for one month reduced LDL-cholesterol by 17 percent, compared to a 13 percent reduction with the same quantity of plant sterol ester. A daily intake of 25 grams of soy protein resulted in a reduction of LDL-cholesterol by only 10 percent.

As a food additive CSPHP is highly stable, retaining its properties even through high temperature food manufacturing processes. Because CSPHP can be added to proteins, lipids, starches, and minerals it can be used as an active health ingredient in a wide range of consumer-acceptable foods, drinks, and dietary supplements.

Japan's Ministry of Health, Labor, and Welfare officially recognizes CSPHP as a 'Food for Specified Health Use (FOSHU FOSHU Foods for Specified Health Use (Japan) ).' For the U.S. market, CSPHP has been self-affirmed GRAS GRAS - A public domain graph-oriented database system for software engineering applications from RWTH Aachen.  (Generally Recognized As Safe Generally Recognized as Safe (GRAS) is a United States of America Food and Drug Administration (FDA) designation that a chemical or substance added to food is considered safe by experts, and so is exempted from the usual Federal Food, Drug, and Cosmetic Act (FFDCA) food ) through an independent evaluation by an expert panel.

About Kyowa Hakko:

Kyowa Hakko (TSE See Tokyo Stock Exchange.

TSE

1. See Tokyo Stock Exchange (TSE).

2. See Toronto Stock Exchange (TSE).
:4151) is an industry leading global supplier to the food, pharmaceutical and chemical industries, with net sales Net Sales

The amount a seller receives from the buyer after costs associated with the sale are deducted.

Notes:
This amount is calculated by subtracting the following items from gross sales: merchandise returned for credit, allowances for damaged or missing goods, freight
 in the fiscal year ending March 31, 2003 of 359 billion yen. The Company was established in 1949 and is headquartered in Tokyo, Japan. Areas of expertise include the development and application of fermentation technology, and new forms of biotechnology. Kyowa Hakko's core pharmaceutical research focuses on drug discovery using antibody-based technologies and on developing therapeutic agents for cancer and allergies. URL URL
 in full Uniform Resource Locator

Address of a resource on the Internet. The resource can be any type of file stored on a server, such as a Web page, a text file, a graphics file, or an application program.
: http://www.kyowa.co.jp/eng/; E-mail: pr@kyowa.co.jp (Attention : Ichiro Matsuura / Manager / Public Relations public relations, activities and policies used to create public interest in a person, idea, product, institution, or business establishment. By its nature, public relations is devoted to serving particular interests by presenting them to the public in the most  / KYOWA HAKKO)
COPYRIGHT 2003 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Sep 24, 2003
Words:651
Previous Article:Endologix Files Final Module of PowerLink PMA Submission, Plans Full PMA Submission to FDA by Year-End.
Next Article:S&P Affirms Manulife -- International -- Ltd. 'AA+' Rtgs.



Related Articles
Garlic: Case Unclosed.(garlic as a dietary supplement)
OREXO PATENT FOR RAPID DELIVERY ISSUED IN EU.
Donald Blaine.(OBITUARIES)
Kyowa Hakko Kogyo, Mitsubishi Pharma Obtain Additional Approval for Recombinant Alteplase Agents.
Kyowa Hakko Kogyo to Release Plant-derived Glucosamine for Commercial Use in September.
Kyowa Hakko Chemical to Increase Production Capacity of 2-Ethyl Hexanoic Acid.
Kyowa Hakko Kogyo Licenses Anti-tumor Drug Candidate Mitotic Kinesin Eg5 Inhibitor to Eli Lilly.
Kyowa Medex Releases Diagnostic Reagent for Type 3 Familial Hyperlipemia.
Kyowa Hakko Develops World's First Fermentation-based Commercial Production Method for L-Tyrosine.
Kyowa Hakko Licenses Anticancer Agent KW-2401 to Keryx Biopharmaceuticals.

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles